Get started
Revance Therapeutics, Inc. 1.75% 15-FEB-2027Revance Therapeutics, Inc. 1.75% 15-FEB-2027Revance Therapeutics, Inc. 1.75% 15-FEB-2027

Revance Therapeutics, Inc. 1.75% 15-FEB-2027

No trades
See on Supercharts
Overview
Analysis News

RVNC5133129 chart


Full chart

Key terms


Outstanding amount
‪287.50 M‬ USD
Face value
1,000.00 USD
Minimum denomination
1,000.00 USD
Coupon
1.75% (Fixed)
Coupon frequency
Semi-annual
Yield to maturity
11.46%
Maturity date
Feb 15, 2027
Term to maturity
2 years

About Revance Therapeutics, Inc. 1.75% 15-FEB-2027


Issuer
Revance Therapeutics, Inc.
Sector
Health Technology
Home page
revance.com
Issue date
Feb 17, 2021
FIGI
BBG00RQ22273
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

RVNC5133129 analysis


Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.

RVNC5133129 news